MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report

1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,JAK2B	SA00067485	47	F	SA00067485
Ordering Phys				**DOB**
CLIENT,CLIENT				06/10/1966
Client Order #	**Account Information**			**Report Notes**
SA00067485				
Collected	C7028846-DLMP Rochester			
05/14/2014 00:00	SDSC 2 - Client Support			
Printed	Rochester, MN 55901			
05/15/2014 14:46				

Test	Flag	Results	Unit	Reference Value	Perform Site*

JAK2 V617F Mutation Detection, B MCR

Peripheral blood, JAK2 V617F mutation analysis:

Positive. JAK2 V617F mutated DNA was detected and measured at 20% of total JAK2 DNA.

JAK2V617F mutation is found with high frequency in Philadelphia chromosome-negative myeloproliferative neoplasms (>95% in polycythemia vera and approximately 50-60% in primary myelofibrosis and essential thrombocythemia). It can also occur in other myeloid neoplasms, such as refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) and rarely in myelodysplastic syndrome, chronic myelomonocytic leukemia, atypical chronic myeloid leukemia and acute myeloid leukemia. Clinicopathologic correlation is recommended for a definitive diagnosis.

The precision of JAK2 mutation percentage measurement is such that values 2 times higher or lower than the reported value are considered equivalent.

Signing Pathologist: Melissa Tricker-Klar
Method summary - JAK2 V617F analysis: Quantitative, allele-specific polymerase chain reaction (PCR) assay was performed using extracted genomic DNA to evaluate for the point mutation causing JAK2 V617F. The analytic sensitivity of this assay has been determined at 0.01% (see Mayo Medical Laboratories Interpretive Handbook for method details).
Laboratory developed test.
PDF Report available at:
https://test.mmlaccess.com/Reports/C7028846-GeZ3emHAx2.ashx

RECEIVED: 05/15/2014 10:15 **REPORTED:** 05/15/2014 12:36

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director:

Patient Name	Collection Date and Time	Report Status
SAMPLEREPORT,JAK2B	05/14/2014 00:00	Final
Page 1 of 1		** End of Report **

* Report times for Mayo performed tests are CST/CDT

MAYO CLINIC
Mayo Medical Laboratories

Performing Site:
Mayo Clinic Laboratories - Rochester Main Campus
200 First Street SW, Rochester MN 55905
Franklin R. Cockerill, M.D. Lab Director
Phone: 800-533-1710
http://www.mayomedicallaboratories.com

SAMPLEREPORT, JAK2B **MEDICAL RECORD # (PATIENT ID)** SA00067485

DOB	06/10/1966	**CLIENT ID/WARD**	7028846	**ORDER #**	C215000227
SEX	Female	**CLIENT/NAME WARD**	DLMP Rochester	**CLIENT ORDER #**	SA00067485
CLIENT MRN	SA00067485	**CITY, ST, ZIP**	Rochester	**DATE COLLECTED**	5/14/2014 12:00 AM
REQUESTED BY	CLIENT CLIENT		MN 55901	**DATE RECEIVED**	5/15/2014 10:15 AM
				DATE REPORTED	5/15/2014 12:36 PM

JAK2 V617F Mutation Detection, B

Interpretation

Peripheral blood, JAK2 V617F mutation analysis:

Positive. JAK2 V617F mutated DNA was detected and measured at 20% of total JAK2 DNA.

*JAK2*V617F mutation is found with high frequency in Philadelphia chromosome-negative myeloproliferative neoplasms (>95% in polycythemia vera and approximately 50-60% in primary myelofibrosis and essential thrombocythemia). It can also occur in other myeloid neoplasms, such as refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS -T) and rarely in myelodysplastic syndrome, chronic myelomonocytic leukemia, atypical chronic myeloid leukemia and acute myeloid leukemia. Clinicopathologic correlation is recommended for a definitive diagnosis.

The precision of JAK2 mutation percentage measurement is such that values 2 times higher or lower than the reported value are considered equivalent.

Signing Pathologist: Melissa Tricker-Klar

Method:

Method summary - JAK2 V617F analysis: Quantitative, allele-specific polymerase chain reaction (PCR) assay was performed using extracted genomic DNA to evaluate for the point mutation causing JAK2 V617F. The analytic sensitivity of this assay has been determined at 0.01% (see Mayo Medical Laboratories Interpretive Handbook for method details).

Disclaimer:

Laboratory developed test.

The collected, received, and reported dates and times on the report are in the time zone of the performing location.

Site ID: C7028846
Accession Number: SA00067485
FileName: SA00067485-7WKfNO
+py219z9P11FbY4KmGITtZkzZ2gYo_tJABi9nxMlNer6Qv9MdozwDIuQyka0gYxIV6KQ_+PVZHLQKRA==.pdf
Reported Date & Time: 05/15/14 12:38
Test Name: JAK2 V617F Mutation Detection, B
Result Name: JAK2 V617F Mutation Detection, B